Brown & Brown Free cash flow decreased by 43.2% to $241.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 23.0%, from $196.00M to $241.00M. Over 4 years (FY 2021 to FY 2025), Free cash flow shows an upward trend with a 16.0% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase suggests improved operational efficiency or reduced capital intensity, providing more flexibility for capital allocation. A decrease may indicate higher investment in R&D or infrastructure, or potential challenges in converting earnings into cash.
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and m...
Large-cap medical device and pharmaceutical peers typically maintain strong, positive free cash flow, though levels vary based on the intensity of R&D spending and the lifecycle stage of major product lines.
free_cash_flow| Q1 '21 | Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $126.60M | $228.20M | $238.40M | $170.60M | $93.60M | $234.30M | $239.50M | $261.60M | $48.00M | $315.00M | $303.00M | $275.00M | $0.00 | $334.00M | $417.00M | $341.00M | $196.00M | $310.00M | $452.00M | $424.00M | $241.00M |
| QoQ Change | — | +80.3% | +4.5% | -28.4% | -45.1% | +150.3% | +2.2% | +9.2% | -81.7% | +556.3% | -3.8% | -9.2% | -100.0% | — | +24.9% | -18.2% | -42.5% | +58.2% | +45.8% | -6.2% | -43.2% |
| YoY Change | — | — | — | — | -26.1% | +2.7% | +0.5% | +53.3% | -48.7% | +34.4% | +26.5% | +5.1% | -100.0% | +6.0% | +37.6% | +24.0% | — | -7.2% | +8.4% | +24.3% | +23.0% |